Physician profile

Michael Boyle

Surgical Oncology · Margate, FL

NPI 1245294552

$2,335.08

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$77.56

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $1,334.55 2019-2023
Acell, INC. $125.00 2019
Baxter Healthcare $125.00 2019
Pacira Pharmaceuticals Incorporated $122.12 2020
Medical Device Business Services, INC. $117.48 2019
Portola Pharmaceuticals, LLC $116.67 2019
Merck Sharp & Dohme LLC $114.52 2019
Kci USA, INC. $113.02 2019
Medline Industries Lp $99.82 2019
Smith+Nephew, INC. $66.90 2022-2024 Grafix Pl, Stravix Pl

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael Boyle

$2,335.08

in general payments reported 2019-2025

Years
2019-2024
Top company
Intuitive Surgical, INC.

https://glasscript.com/doctor/398433/michael-boyle

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.